Equities

Krebs Biochemicals and Industries Ltd

KREBSBIO:NSI

Krebs Biochemicals and Industries Ltd

Actions
Consumer Staples Food Producers
  • Price (INR)73.40
  • Today's Change1.85 / 2.59%
  • Shares traded1.65k
  • 1 Year change+3.38%
  • Beta0.9882
Data delayed at least 15 minutes, as of Apr 26 2024 07:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Krebs Biochemicals & Industries Ltd is an India-based company, which is engaged in the business of manufacture of active pharmaceutical ingredients. The Company manufactures bulk active pharmaceutical ingredients, pharmaceutical intermediates, fine chemicals, nutraceuticals utilizing two revenue streams: contract manufacturing for large pharmaceutical and multinational companies, and development of its products for sale in global markets. Its products include Androstenedione, Lovastatin, and Simvastatin. The Company’s pilot or research and development stages products are Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan, and Phenylephrine. The Company has two manufacturing facilities one at Regadichelaka, Nellore District and another one at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.

  • Revenue in INR (TTM)499.09m
  • Net income in INR-208.21m
  • Incorporated1991
  • Employees210.00
  • Location
    Krebs Biochemicals and Industries LtdInwinex Towers, Plot No. 130, 4th FloorRoad No. 2, Regadichelika VillageBanjara HillsHYDERABAD 500034IndiaIND
  • Phone+91 4 066808040
  • Fax+91 4 023540320
  • Websitehttp://krebsbiochem.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lasa Supergenerics Ltd1.17bn-214.42m1.29bn89.00------1.10-4.28-4.2823.30--------13,128,270.00---2.61---3.7529.7432.34-18.35-3.67---0.949-----5.51-12.02-624.41------
Sotac Pharmaceuticals Ltd579.83m44.96m1.37bn89.0022.238.6722.392.365.585.5860.6914.31----------------30.90--7.75--0.99688.620.4806---20.74--56.17------
Aarey Drugs and Pharmaceuticals Ltd3.48bn42.19m1.42bn0.0032.03--26.130.42911.661.66137.72------------2.78--5.844.173.661.211.52--1.63-----14.963.70-42.38-9.4010.95--
Krebs Biochemicals And Industries Ltd499.09m-208.21m1.56bn210.00------3.09-9.50-9.5022.86--------2,376,624.00---18.88---29.0486.2811.95-41.72-59.37---3.78-----12.689.0744.55--28.63--
Bal Pharma Ltd3.27bn35.19m1.59bn--45.27--11.480.4752.172.17209.85------------0.1785--0.478244.0243.811.080.1865--1.34--132.388.187.54-54.17-1.5631.090.00
Mangalam Drugs and Organics Ltd3.57bn-169.87m1.61bn523.00------0.4461-10.74-10.74225.21--------6,834,930.00--3.70--6.5026.3829.07-4.752.87---0.5682-----17.475.91-93.54-42.3211.78--
Vaishali Pharma Ltd801.21m58.38m1.73bn--30.83--26.792.135.155.1568.64------------3.32--8.6417.7215.067.293.71--4.37-----8.120.507264.1252.62-4.18--
Data as of Apr 26 2024. Currency figures normalised to Krebs Biochemicals and Industries Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.